ISCP: A to Z of CV Pharmacotherapy Webinar Series
Published: 26 May 2022
1h 3m 35sPart 1 Ferric Carboxymaltose: Ironing Out the Issues Around Heart Failure Related Readmissions David Sim, Maurizio Volterrani, Chan Hong, Daniel Lighezan, Franco Cheng
1h 4m 39sPart 2 Inclisiran: A Jab Goes a Long Way Krzysztof Filipiak, Bernard Man Yung Cheung, Alberto Lorenzatti, Krittin Banditanukul, Doreen Su-Yin Tan
1h 1m 55sPart 3 Edoxaban: ENGAGEing in Individualisation of DOACs Gheorghe-Andrei Dan, Doreen Su-Yin Tan, Oskars Kalējs, Ann Leung, Claire Lew
53m 45sPart 4 Valsartan Sacubitril: Has our PARADIGM shifted? Giuseppe Rosano, Richard Henry P Tiongco, Rungroj Krittayaphong, Janice Wong Yii Ching , Doreen Su-Yin Tan
59m 32sPart 5 Clopidogrel or Ticagrelor: Why, When, for Whom? Diana Gorog, Sotiris Antoniou , Franco Cheng, Craig Beavers
The International Society of Cardiovascular Pharmacotherapy (ISCP) are pleased to present a collection of six webinars as part of their A to Z of Pharmacotherapy Series.
Published every other month until Dec 2022, these 60-min webinars feature expert panellists, speakers and moderators with live Q&A audiences and EBAC accreditation (1 CME point) for all live views.
This series is ideal for doctors, nurses, pharmacists, family physicians, internists, healthcare students and cardiovascular therapy researchers.
We value your opinion. Take 3 minutes to give us feedback on the series.
More from this programme
About the episode
Beta-blockers are routinely prescribed often as first-line therapy for various cardiovascular diseases such as coronary heart disease and heart failure. Much of their prescribing relates to the benefits of the newer generation of beta-blockers and greater cardio-selectivity. One of the challenges all clinicians face is to manage the choice of numerous beta-blockers and in particular translating the evidence base to real-world practice.
This webinar will provide an overview of the evidence of beta-blockers, and present some key differences between the agents. The webinar will also discuss, through the use of cases, the management of patients who are often excluded from clinical trials, in particular the elderly.
This is an independent activity run by the International Society of Cardiovascular Pharmacotherapy (ISCP) and co-produced in collaboration with Radcliffe Cardiology.
Bernard Man Yung Cheung
Bernard Man Yung Cheung is a Professor in Cardiovascular Therapeutics and heads the Division of Clinical Pharmacology and Therapeutics in the Department of Medicine at the University of Hong Kong's School of Clinical Medicine.
His research interests primarily focus on cardiovascular diseases and risk factors, including hypertension and metabolic syndrome.
Professor Yeh also serves as the Chief Editor for the Postgraduate Medical Journal (PMJ) and previously held the position of Chief Editor for Open Diabetes and the World Journal of Hypertension.
Sang Hong Baek
Professor Sang Hong Baek, MD, PhD, FACC, FESC, is an Emeritus Professor at The Catholic University of Korea and the President of the International Society of Cardiovascular Pharmacotherapy (2023).
He has held several prestigious positions, including former President of the Korean Society of Lipid and Atherosclerosis, Korean Society of Cardio Cerebrovascular Disease Prevention, and Korean Society of Cardiovascular Pharmacotherapy.
Professor Baek also serves as an editorial board member for several cardiovascular journals, including the European Heart Journal (EHJ), where he is an Associate Editor for EHJ-Cardiovascular Pharmacotherapy, as well as the International Journal of Cardiology and Current Hypertension Reports.
Specialist in: cardiology, internal medicine, arterial hypertension, clinical pharmacology (4 certified specializations).
Education: Medical University of Warsaw (MUW), MD, PhD.
Scientific and clinical internships: Medical Faculty, Utrecht University, Netherlands, Medical Faculty, Amsterdam University, Netherlands, Internal Medicine Department, Gaffree e Guinle University, Rio de Janeiro, Brazil, Department of Pharmacology, University of Geneva, Switzerland; Erasmus Programme for University Teachers'…
Consultant Pharmacist & Lead Cardiovascular Pharmacist
Mr Sotiris Antoniou is Consultant Pharmacist at Barts Heart Centre, part of Barts Health NHS Trust. Combined with his role as Lead Cardiovascular Pharmacist for UCL Partners supports medicines optimisation across the health economy to optimise patient outcomes and address unmet local needs. He is an independent prescriber and is currently chair of the cardiac committee for United Kingdom Clinical Pharmacy Association (UKCPA). He is chair of the DRM-foundation that supports the international Pharmacist Anticoagulation Taskforce (iPACT). A group aimed to improve pharmaceutical care around anticoagulants, by providing background materials and stimulating pharmacists to provide appropriate care to their patients.
He has published extensively in the medical press and has a particular interest in improving anticoagulation for stroke prevention in atrial fibrillation…